1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Arno Therapeutics, Inc.US flagOther OTC
0.00
USD
- -
- -
9,870.00Market Cap
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
TTM
Revenue per Share
- -
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.16
-0.05
-0.07
-0.07
0.03
-6.45
-2.72
-1.67
-1.85
-3.17
-5.28
0.38
-0.56
-0.33
Free Cash Flow per Basic Share
-0.06
-0.02
-0.12
-0.04
0.02
-4.45
-2.87
-1.38
-1.59
-2.07
-1.89
-0.92
-0.49
-0.18
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.56
-0.61
-0.68
-0.75
-2.99
-8.31
-9.25
-10.82
-8.23
-10.99
-11.91
-4.01
-4.57
-2.47
Tangible Book Value per Share
-0.18
-0.21
-0.16
-0.22
-2.91
3.93
0.62
3.31
0.31
-2.7
-1.71
-0.03
-0.42
-0.14
Basic Weighted Avg Shares
- -
- -
- -
- -
1
2
3
3
4
5
8
20
20
42
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-2,329.48
-838.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
-13
-7
-4
-8
-14
-40
8
-12
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-2,329.48
-838.82
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
8
1
12
5
8
23
6
-4
1
LT Debt
- -
- -
- -
- -
4
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
- -
-4
8
2
8
1
-12
-13
-1
-9
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-9.07
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'16
Jun'16
Sep'16
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
48
Market Capitalization
10
10
20

Working Capital

FRC

•

in mil. unless spec.
Mar'16
Jun'16
Sep'16
Total Current Assets
3
1
2
Cash, Cash Equivalents & STI
3
1
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
2
2
Payables & Accruals
1
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
727.58%
37.07%
1,364.46%
Free Cash Flow
-4,059.16%
33.55%
-47.06%
Net Income, GAAP
-3,523.7%
-2.71%
-248.09%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
-0.02
0.17
0.01
- -
0.38
2015
-0.17
-0.17
-0.03
- -
-0.56
2016
-0.1
-0.05
-0.09
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David M. Tanen
Full Time Employees
4
Sector
Healthcare
Industry
Biotechnology
Address
200 Route 31 North Flemington NJ United States of America 08822
IPO Date
Jun 11, 2008
Website
arnothera.com
Similar Companies
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
Sprint Bioscience AB (publ) (SPRINT.ST)
Synovics Pharmaceuticals, Inc. (SYVC)
Enimmune corporation (6564.TWO)
Abpro Holdings, Inc. (ABPO)
Chemomab Therapeutics Ltd. (CMMB)
Business
Arno Therapeutics, Inc. functioned as a biopharmaceutical firm, historically dedicated to advancing therapeutic solutions for oncology and other critical medical conditions. The company's development portfolio once featured Onapristone, a type 1 anti-progestin hormone blocker, which was undergoing Phase I/II clinical investigation for treating breast and endometrial cancers, various solid tumors in post-menopausal women, and advanced castration-resistant prostate cancer in men. Additionally, its investigational pipeline included AR-12, an orally administered cancer treatment that had progressed through a Phase I clinical study for solid tumors and hematological malignancies, alongside preclinical evaluations for diverse anti-microbial applications. A further compound, AR-42, represented an innovative oral cancer therapy then in an investigator-initiated Phase I clinical study, targeting hematological malignancies and solid tumors. Arno Therapeutics also held various agreements, including licensing arrangements with entities such as Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation, alongside a co-development pact with Leica Biosystems Newcastle Ltd. However, the company concluded its operations, selling its remaining assets, most notably the rights to Onapristone to Context Biopharma, Inc., and officially initiated a plan of liquidation and dissolution by late 2017. Arno Therapeutics, Inc. subsequently deregistered its common stock and ceased to exist as an operational entity.